A project led by a young, tenured solid organ transplant (SOT) researcher from ImmunoConcEpT laboratory, Dr. Jonathan Visentin, has been awarded by an EU’s Marie Sklodowska-Curie Actions Global Fellowship (MSCA-GF). This 3 year project is called “DABAT” (DNA-sensing by AIM2 in activated B cells: novel targets to improve Allogeneic haematopoietic stem cell Transplantation, grant number 888743). For the first 2 years Dr. Visentin will join Dr. Stefanie Sarantopoulos’ laboratory at Duke University in Durham, North Carolina, USA. Dr. Sarantopoulos specializes in B cell signaling in patients with hematolymphoid malignancies who have undergone allogeneic hematopoietic stem cell transplantation (allo-HCT) and develop chronic graft-versus-host disease (GVHD). Chronic GVHD is a significant cause of non-cancer relapse morbidity and mortality after allo-HCT for which there is an urgent need for more effective treatments. This EU grant affords a great opportunity for two B cell experts to share knowledge about immune tolerance loss and pathogenic antibody production in allo-HCT and SOT. Moreover, this innovative project has incited a new collaboration that Dr. Visentin will pursue at ImmunoConcEpT during the third year of funding in collaboration with Drs. Vanja Sisirak and Edouard Forcade. In addition to creating new international collaborations, inside and outside the EU, the MSCA-GF awards are delivered by the EU to provide select researchers expanded training needed for professional maturity/independence.